Are Antisense Long Non-Coding RNA Related to COVID-19?

Badr, Eman; Sayed, Ibrahim Eltantawy El; Gabber, Mohanad Kareem Razak; Ghobashy, Eman Abd Elrehem; Al‐Sehemi, Abdullah G.; Algarni, H.; Elghobashy, Yasser AS

doi:10.3390/biomedicines10112770

Cited by 7 publications

(5 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A2M-AS1 probably has an anti-proliferation and pro-apoptosis effect [37], and LEF1-AS1 and RORA-AS-1 have been found to be involved in T cell differentiation in COVID-19 patients [38]. The decreased levels of A2M-AS-1 in severe COVID-19 patients are in accordance with a previous study [39].…”

Section: Discussionsupporting

confidence: 90%

Dynamics of Gene Expression Profiling and Identification of High-Risk Patients for Severe COVID-19

Rombauts,

Bódalo Torruella,

Abelenda-Alonso

et al. 2023

Biomedicines

View full text Add to dashboard Cite

The clinical manifestations of SARS-CoV-2 infection vary widely, from asymptomatic infection to the development of acute respiratory distress syndrome (ARDS) and death. The host response elicited by SARS-CoV-2 plays a key role in determining the clinical outcome. We hypothesized that determining the dynamic whole blood transcriptomic profile of hospitalized adult COVID-19 patients and characterizing the subgroup that develops severe disease and ARDS would broaden our understanding of the heterogeneity in clinical outcomes. We recruited 60 hospitalized patients with RT-PCR-confirmed SARS-CoV-2 infection, among whom 19 developed ARDS. Peripheral blood was collected using PAXGene RNA tubes within 24 h of admission and on day 7. There were 2572 differently expressed genes in patients with ARDS at baseline and 1149 at day 7. We found a dysregulated inflammatory response in COVID-19 ARDS patients, with an increased expression of genes related to pro-inflammatory molecules and neutrophil and macrophage activation at admission, in addition to an immune regulation loss. This led, in turn, to a higher expression of genes related to reactive oxygen species, protein polyubiquitination, and metalloproteinases in the latter stages. Some of the most significant differences in gene expression found between patients with and without ARDS corresponded to long non-coding RNA involved in epigenetic control.

show abstract

Section: Discussionsupporting

confidence: 90%

Dynamics of Gene Expression Profiling and Identification of High-Risk Patients for Severe COVID-19

Rombauts,

Bódalo Torruella,

Abelenda-Alonso

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…In Dr. Hong's studies in 2022, it was shown that this LncRNA is a positive regulatory factor with an increased expression pattern to promote breast cancer metastasis (17). Through the interaction with PCBP3(18), increasing the expression in the diagnosis of progression and prognosis of breast cancer (19), decreasing the expression level of A2M-AS1 in the lung tissue of patients with COVID-19 severe compared to control subjects (20). In the studies of Dr. Guo in 2022, it was shown that the overexpression of A2M-AS1 through the regulation of miR-587/bmp3 inhibits cell growth and invasion in lung adenocarcinoma (19).…”

Section: Discussionmentioning

confidence: 99%

Initial evaluation of LncRNA A2M-AS1 gene expression in multiple sclerosis patients

Mohammadi,

Azadeh,

Saeghyian

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction: Multiple sclerosis (MS) is one of the three leading neurodegenerative diseases worldwide. Genes expression profiles studies play important role in recognition and prevention of disease. Considering the inherent ability of biomarkers to diagnose and prognosis the occurrence of a disease, with the aim of gene therapy and changing gene expression, it can be helped to treat it. In this study, by examining the gene interaction and expression of non-coding gene in patients with multiple sclerosis, using bioinformatics analyzes and laboratory research, to find the gene expression pattern and the interaction of potential biomarkers of this disease for It was tried to find suitable treatment targets. Materials and methods: First, by using microarray data analysis of GEO database, the expression status of Lnc RNA A2M-AS1 gene was investigated in patients with MS. Then lncRNA-mRNA interaction analysis was performed in the lncRRisearch and ENCORI database. After sample collection, the total RNA extracted using the RNA extraction kit from 20 patient samples and 20 healthy samples was synthesized into cDNA with the synthesis kit. In the following, two pairs of forward and reverse primers were designed for A2M-AS1 gene, and finally, the expression level was measured by Real Time-PCR technique. Result: Based on bioinformatic and laboratory analysis, the expression of A2M-AS1 gene in MS samples showed a significant decrease in expression compared to healthy samples. Also, based on the ROC analysis, lncRNA A2M-AS1 can be introduced as an acceptable diagnostic biomarker to distinguish MS samples from healthy samples. Conclusion: lncRNA A2M-AS1 by reducing its expression as an acceptable diagnostic biomarker can increases the risk of developing MS.

show abstract

“…Zhong et al showed that the lncRNAs expression profile may identify between severe and non-severe COVID-19 cases, as well as between healthy people and infected patients (Zhong et al, 2022). Measurement of expression of the lncRNAs levels may help predict and monitor patient treatment, according to research by Badr et al that found A2M-AS1 and NCBP2AS1-1 to be useful in differentiating between severe and moderate SARS-CoV-2 infections (Badr et al, 2022). Cheng et al developed a 7-lncRNA panel with a good differential ability between severe and non-severe COVID-19 patients.…”

Section: Ncrnas As Diagnostic Biomarkersmentioning

confidence: 99%

The regulation of lncRNAs and miRNAs in SARS-CoV-2 infection

Lin¹,

Sun²,

Bao³

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) was a global endemic that continues to cause a large number of severe illnesses and fatalities. There is increasing evidence that non-coding RNAs (ncRNAs) are crucial regulators of viral infection and antiviral immune response and the role of non-coding RNAs in SARS-CoV-2 infection has now become the focus of scholarly inquiry. After SARS-CoV-2 infection, some ncRNAs’ expression levels are regulated to indirectly control the expression of antiviral genes and viral gene replication. However, some other ncRNAs are hijacked by SARS-CoV-2 in order to help the virus evade the immune system by suppressing the expression of type I interferon (IFN-1) and controlling cytokine levels. In this review, we summarize the recent findings of long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) among non-coding RNAs in SARS-CoV-2 infection and antiviral response, discuss the potential mechanisms of actions, and prospects for the detection, treatment, prevention and future directions of SARS-CoV-2 infection research.

show abstract

Are Antisense Long Non-Coding RNA Related to COVID-19?

Cited by 7 publications

References 65 publications

Dynamics of Gene Expression Profiling and Identification of High-Risk Patients for Severe COVID-19

Dynamics of Gene Expression Profiling and Identification of High-Risk Patients for Severe COVID-19

Initial evaluation of LncRNA A2M-AS1 gene expression in multiple sclerosis patients

The regulation of lncRNAs and miRNAs in SARS-CoV-2 infection

Contact Info

Product

Resources

About